Intestinal metaplasia

New study shows that WATS3D increases diagnostic yield of dysplasia in Barrett's esophagus, regardless of segment length

Retrieved on: 
Mercredi, août 2, 2023
Male, ASGE, University, Diagnosis, Barrett's esophagus, American Society for Gastrointestinal Endoscopy, Pathology, Intestinal metaplasia, Gastrointestinal Endoscopy, MBA, University of Rochester Medical Center, Consultant, Nature Reviews Gastroenterology & Hepatology, Gastrointestinal tract, Dysplasia, Hepatology, Patient, Division, Gastroenterology, GIE, Epithelium, Northwell Health, Society, Medical device, Endoscopy, MD, Fellowship of the Royal Colleges of Surgeons

Regardless of segment length, WATS3D is highly effective at increasing the diagnostic yield of intestinal metaplasia and dysplasia.

Key Points: 
  • Regardless of segment length, WATS3D is highly effective at increasing the diagnostic yield of intestinal metaplasia and dysplasia.
  • "WATS3D has previously shown diagnostic effectiveness for patients with known or suspected BE," said the lead author of the study, Dr. Arvind Trindade, Regional Director of Endoscopy, Northwell Health.
  • "This new study focuses on WATS3D performance in short versus long segment esophageal columnar-lined mucosa."
  • The adjunctive and absolute yields of WATS3D were calculated according to the length of the patient's BE segment.

WATS3D Technology Demonstrates Utility as Adjunct to Forceps Biopsies in Post-Eradication Surveillance of Barrett's Esophagus Patients

Retrieved on: 
Mardi, janvier 17, 2023
EET, Gastrointestinal Endoscopy, Cancer, American Society for Gastrointestinal Endoscopy, ASGE, BE, MD, Diagnosis, Barrett's esophagus, Epithelium, Metaplasia, Esophagus, Intestinal metaplasia, Endoscopy, Woman, Patient, Utility, Biopsy, Society, Physician, Health, Registry, Medical device, Medical imaging, Dysplasia

SUFFERN, N.Y., Jan. 17, 2023 /PRNewswire/ -- CDx Diagnostics, Inc., developer of the WATS3D AI Platform for the detection and surveillance of Barrett's esophagus (BE) and dysplasia, announced the publication of a new study, Utility of WATS-3D as an Adjunct to Forceps Biopsies in Surveillance of Barrett's Patients Post Endoscopic Eradication Therapy, in the American Society for Gastrointestinal Endoscopy (ASGE) journal iGIE by authors F. Scott Corbett MD, FASGE, Robert D. Odze MD, and Matthew J. McKinley MD. The efficacy of WATS3D has been demonstrated in numerous studies for both the screening and surveillance of BE and dysplasia, both long and short segment. This new study highlights the utility of WATS3D, - concluding that it increases the diagnostic yield of Intestinal Metaplasia (IM) and dysplasia in BE patients after ablation or endoscopic eradication therapy when used as an adjunct to forceps biopsy (FB) sampling. The WATS3D adjunctive yield for detection of residual/recurrent IM or dysplasia was 52.5% and 91.5%, respectively. 

Key Points: 
  • The efficacy of WATS3D has been demonstrated in numerous studies for both the screening and surveillance of BE and dysplasia, both long and short segment.
  • The WATS3D adjunctive yield for detection of residual/recurrent IM or dysplasia was 52.5% and 91.5%, respectively.
  • Adjunctive Use of WATS3D Improves Diagnostic Yield of IM and Dysplasia Missed by Random Forceps Biopsy.
  • The WATS3D AI Platform collects a wide area, disaggregated tissue specimen of the entire thickness of the epithelium being tested.

The global smart pills market was valued at $257 million in 2017, and is expected to reach $650 million by 2025, registering a CAGR of 12.1% from 2018 to 2025

Retrieved on: 
Mardi, octobre 23, 2018
Gastroenterology, Medicine, Health, Gastroesophageal reflux disease, RTT, Barrett's esophagus, Gastrointestinal disease, Gerd, Adherence, Esophagus, Esophageal disease, Intestinal metaplasia

Smart pills are widely being used for the diagnosis of various gastrointestinal disorders such as Barrett's Esophagus, Irritable Bowel Syndrome, GERD (Gastroesophageal reflux disease) and others.

Key Points: 
  • Smart pills are widely being used for the diagnosis of various gastrointestinal disorders such as Barrett's Esophagus, Irritable Bowel Syndrome, GERD (Gastroesophageal reflux disease) and others.
  • Smart pills find applications in solving the problem of medication non-adherence and enables the doctor to track the medication consumption patterns of a patient.
  • The global smart pills market is segmented based on application, target area, disease indication, end user, and region.
  • An extensive analysis of the key segments of the industry helps to understand the trends in the smart pills market globally.